Who is sponsoring NCT06897475?

NCT06897475 is sponsored by Eli Lilly and Company.

What condition does NCT06897475 study?

NCT06897475 studies Type 2 Diabetes.

What drugs are being tested in NCT06897475?

Interventions: LY3457263, Placebo.

What is the status of NCT06897475?

NCT06897475 is currently RECRUITING.

Last reviewed 2026-04-16 · How we verify

A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal

NCT06897475 Phase 2 RECRUITING

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	RECRUITING
Enrolment	240
Start date	2025-03-28
Completion	2027-01

Conditions

Type 2 Diabetes

Interventions

LY3457263
Placebo

Primary outcomes

Change from Baseline in Hemoglobin A1c (HbA1c) — Baseline, Week 24

Countries

United States, Canada, Germany, Poland, Puerto Rico, United Kingdom